UA29469C2 - Ліпосомальна фармацевтична композиція для внутрішньовенного введення - Google Patents

Ліпосомальна фармацевтична композиція для внутрішньовенного введення

Info

Publication number
UA29469C2
UA29469C2 UA95094063A UA95094063A UA29469C2 UA 29469 C2 UA29469 C2 UA 29469C2 UA 95094063 A UA95094063 A UA 95094063A UA 95094063 A UA95094063 A UA 95094063A UA 29469 C2 UA29469 C2 UA 29469C2
Authority
UA
Ukraine
Prior art keywords
intravenous administration
pharmaceutical compositions
liposomal pharmaceutical
liposomal
phospholipid
Prior art date
Application number
UA95094063A
Other languages
English (en)
Russian (ru)
Inventor
Ханс-Юрген ХАМАНН
Петер Зерно
Маттіас Хербот
Маттиас Хербот
Петер Курка
Original Assignee
Байєр Аг
Байер Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байєр Аг, Байер Аг filed Critical Байєр Аг
Publication of UA29469C2 publication Critical patent/UA29469C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glass Compositions (AREA)
  • External Artificial Organs (AREA)

Abstract

Винахід стосується ліпосомальних фармацевтичних композицій для внутрішньовенного введення. Пропонована ліпосомальна фармацевтична композиція для внутрішньовенного введення містить ліофільну слабко розчинну активну речовину у вигляді ліпосом із середнім діаметром 35-200 нм, хоча б один фосфоліпід, дистильовану воду і цільові добавки.
UA95094063A 1994-09-12 1995-09-06 Ліпосомальна фармацевтична композиція для внутрішньовенного введення UA29469C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4432378A DE4432378A1 (de) 1994-09-12 1994-09-12 Injizierbare liposomale Arzneizubereitungen

Publications (1)

Publication Number Publication Date
UA29469C2 true UA29469C2 (uk) 2000-11-15

Family

ID=6527981

Family Applications (1)

Application Number Title Priority Date Filing Date
UA95094063A UA29469C2 (uk) 1994-09-12 1995-09-06 Ліпосомальна фармацевтична композиція для внутрішньовенного введення

Country Status (28)

Country Link
US (1) US5653998A (uk)
EP (1) EP0700679B1 (uk)
JP (1) JPH0881361A (uk)
KR (1) KR960009998A (uk)
CN (1) CN1079668C (uk)
AT (1) ATE187327T1 (uk)
AU (1) AU698441B2 (uk)
CA (1) CA2157849A1 (uk)
CZ (1) CZ287975B6 (uk)
DE (2) DE4432378A1 (uk)
DK (1) DK0700679T3 (uk)
EE (1) EE03377B1 (uk)
ES (1) ES2139800T3 (uk)
FI (1) FI954204A (uk)
GR (1) GR3032664T3 (uk)
HU (1) HUT73808A (uk)
IL (1) IL115222A (uk)
MY (1) MY111841A (uk)
NO (1) NO311556B1 (uk)
NZ (1) NZ272943A (uk)
PL (1) PL181541B1 (uk)
PT (1) PT700679E (uk)
RU (1) RU2160099C2 (uk)
SI (1) SI0700679T1 (uk)
SK (1) SK281611B6 (uk)
TW (1) TW359616B (uk)
UA (1) UA29469C2 (uk)
ZA (1) ZA957604B (uk)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
KR20000003433A (ko) * 1998-06-29 2000-01-15 김영환 반도체소자의 커패시터 제조방법
CA2350430C (en) * 1998-11-13 2008-06-03 Optime Therapeutics, Inc. Method and apparatus for liposome production
JP2003508349A (ja) * 1999-05-14 2003-03-04 エスペリオン エルユーブイ ディベロップメント， インコーポレイテッド アンギナおよび／またはアンギナ等価状態を処置する方法、ならびにそれに関連する薬学的組成物およびキット
ES2272496T3 (es) 2000-02-04 2007-05-01 Lipoxen Technologies Limited Procedimiento de deshidratacion/rehidritacion para la preparacion de lipososmas.
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
EP2108362B1 (en) 2002-06-26 2013-05-29 MediGene AG A cationic liposomal preparation comprising a taxane
DE10255195A1 (de) * 2002-11-27 2004-06-09 Lipoid Gmbh Micellare wasserlösliche Konzentrate
US20060222694A1 (en) * 2003-06-27 2006-10-05 Oh Choon K Stabilized topotecan liposomal composition and methods
US7345093B2 (en) * 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US20080095834A1 (en) * 2005-03-02 2008-04-24 Volkmar Weissig Mitochondriotropic Phospholipid Vesicles
MX2007015577A (es) * 2005-06-09 2008-02-25 Biolipox Ab Metodo y composiciones para el tratamiento de trastornos inflamatorios.
US8445007B2 (en) 2005-09-22 2013-05-21 Medivas, Llc Bis-(α-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use
EP1933881B1 (en) 2005-09-22 2019-03-13 Medivas, LLC Solid polymer delivery compositions and methods for use thereof
EP2034961A1 (de) * 2006-06-30 2009-03-18 Gertrud Langhoff Solubilisatformulierungen
JP6081058B2 (ja) * 2009-03-19 2017-02-15 第一三共株式会社 包装により安定保存された固形製剤
US20110070294A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
EP2480208A1 (en) 2009-09-23 2012-08-01 Indu Javeri Methods for the preparation of liposomes
IT1404011B1 (it) 2010-12-03 2013-11-08 Uni Degli Studi Magna Graecia Di Catanzaro Nanovettore coniugato con tsh per il trattamento del cancro della tiroide
PL226015B1 (pl) * 2011-03-03 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
EP3159368B1 (en) 2011-06-23 2024-07-24 DSM IP Assets B.V. New biodegradable polyesteramide copolymers for drug delivery
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
FR2979239A1 (fr) * 2011-08-25 2013-03-01 Trophos Liposome comprenant au moins un derive de cholesterol
EP2682106A1 (en) 2012-07-03 2014-01-08 Phares Pharmaceutical Research N.V. Method of solubilizing biologically active compounds
CA2893342A1 (en) * 2012-12-06 2014-06-12 D & J Rosee Inc. Topical liposome compositions containing phenolic anti-inflammatory agents and their methods of preparation
CN107106509B (zh) 2014-12-18 2021-11-30 帝斯曼知识产权资产管理有限公司 用于递送酸敏感药物的药物递送系统
CN110898011B (zh) * 2019-11-27 2022-02-08 西南医科大学 一种依托咪酯纳米制剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3515335C2 (de) * 1985-04-27 1995-01-26 Bayer Ag Arzneizubereitung enthaltend Dihydropyridine und Verfahren zu ihrer Herstellung
DE4117750A1 (de) * 1991-05-30 1992-12-24 Bayer Ag Neue 2-amino-5-cyano-1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE4207481A1 (de) * 1992-03-10 1993-09-16 Bayer Ag Liposomale wirkstoff-formulierungen und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
NO953578D0 (no) 1995-09-11
PL310344A1 (en) 1996-03-18
CZ234195A3 (en) 1996-03-13
CN1128655A (zh) 1996-08-14
CA2157849A1 (en) 1996-03-13
FI954204A (fi) 1996-03-13
AU3046495A (en) 1996-03-28
IL115222A0 (en) 1995-12-31
DE4432378A1 (de) 1996-03-14
NO953578L (no) 1996-03-13
JPH0881361A (ja) 1996-03-26
HUT73808A (en) 1996-09-30
SK112795A3 (en) 1997-02-05
KR960009998A (ko) 1996-04-20
CN1079668C (zh) 2002-02-27
CZ287975B6 (cs) 2001-03-14
ES2139800T3 (es) 2000-02-16
ZA957604B (en) 1996-04-15
RU2160099C2 (ru) 2000-12-10
EE03377B1 (et) 2001-04-16
NO311556B1 (no) 2001-12-10
MY111841A (en) 2001-01-31
TW359616B (en) 1999-06-01
US5653998A (en) 1997-08-05
EE9500063A (et) 1996-04-15
IL115222A (en) 1999-06-20
FI954204A0 (fi) 1995-09-08
EP0700679B1 (de) 1999-12-08
HU9502654D0 (en) 1995-11-28
AU698441B2 (en) 1998-10-29
SI0700679T1 (en) 2000-02-29
DE59507372D1 (de) 2000-01-13
PL181541B1 (pl) 2001-08-31
PT700679E (pt) 2000-05-31
GR3032664T3 (en) 2000-06-30
ATE187327T1 (de) 1999-12-15
DK0700679T3 (da) 2000-05-29
EP0700679A1 (de) 1996-03-13
NZ272943A (en) 1996-07-26
SK281611B6 (sk) 2001-05-10

Similar Documents

Publication Publication Date Title
UA29469C2 (uk) Ліпосомальна фармацевтична композиція для внутрішньовенного введення
WO1995017876A3 (en) 2,4-disulphophenyl butylnitrone, its salts, and their use as pharmaceutical spintraps
CA2156288A1 (en) Glycerol derivative, device and pharmaceutical composition
CA2339765A1 (en) Compounds and compositions for delivering active agents
ZA962536B (en) Pharmaceutical composition for transdermal administration.
MX9706449A (es) Composicion farmaceutica para compuestos de piperidinalcanol.
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
CA2294783A1 (fr) Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine
PT975235E (pt) Formulacoes nutricionais contendo oligossacaridos
AU2845599A (en) Pharmaceutical compositions and their use
CA2180571A1 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
AU3904193A (en) Liposome composition
CA2270177A1 (en) Transdermal administration of ment
AU607496B2 (en) Pharmaceutical compositions
FI945807A (fi) 2,5-diokso-2,5-dihydro-1H-bents/b/atsepiinit NMDA-reseptorin antagonisteina
HUP0004362A2 (hu) Karbamazepint vagy származékait tartalmazó parenterális készítmények
FR2685204B1 (fr) Compositions pharmaceutiques pour l'administration transcutanee de la fenfluramine.
UA32583C2 (uk) Похідні арилтіоалкілтіопіридину
ES8801267A1 (es) Procedimiento para preparar derivados de isoquinolinona
ES2175086T3 (es) Composiciones farmaceuticas anti-emeticas que contienen metotrimeprazina.
CA2373166A1 (en) Antiulcer agent
IL105685A (en) Multi-layered, microencapsulated pharmaceutical composition
YU49496B (sh) 2,4-disulfofenil butil nitron, njegove soli, i njihova primena kao farmaceutskih kompozicija
PH30738A (en) Anti-allergic pharmaceutical composition for ophthamic topical administration.
ZA967815B (en) Nanodispersions for the intravenous administration of an aneasthetic agent having lipophilic properties